Perspective Therapeutics, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Johan Spoor
- Full Time Employees
- 138
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 350 Hills Street Seattle WA United States of America 99354
- IPO Date
- Nov 10, 2005
- CIK
- 0000728387
- Website
- perspectivetherapeutics.com
- Similar Companies
- Business
- Perspective Therapeutics, Inc. (NYSE American: CATX) develops and commercializes precision targeted alpha therapies (TATs) using proprietary Pb-212-based alpha-particle radiopharmaceuticals for cancer treatment in the United States. The company offers image-guided theranostics leveraging chemically matched Pb-203/Pb-212 isotope pairs conjugated to high-affinity tumor-specific peptides via a proprietary Pb-specific chelator; core pipeline candidates include VMT-α-NET in Phase 1/2a for SSTR2-expressing neuroendocrine tumors, VMT01 in Phase 1/2a for MC1R-positive metastatic melanoma, and earlier-stage programs targeting additional solid tumors such as those expressing melanocortin 1 receptor or somatostatin receptors; complementary imaging diagnostics enable tumor visualization and patient selection prior to alpha therapy delivery; a proprietary 212Pb generator supports isotope supply for clinical trials and commercial-scale production. Founded in 1983 and headquartered in Seattle, Washington, the company operates primarily in the radiopharmaceutical sector with ongoing clinical trials at leading academic institutions and expanding manufacturing capabilities across regional facilities. Recent developments include first patient dosing with [212Pb]VMT01 monotherapy at 1.5 mCi in its Phase 1/2a melanoma study in April 2025; dosing of eight patients into Cohort 3 (6.0 mCi) of the VMT-α-NET study within three months of opening in June 2025; presentation of updated interim Phase 1/2a data for VMT-α-NET at ESMO Congress 2025 showing no dose-limiting toxicities in 55 patients and eight confirmed responses in Cohort 2; cash position of $227 million as of December 31, 2024, bolstered by prior fundraising including an $87.4 million private placement in March 2024, funding operations into late 2026 amid scaling of manufacturing sites acquired recently.
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
Perspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) Financial Contrast
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Comparing Perspective Therapeutics (NASDAQ:CATX) & Biosig Technologies (NASDAQ:STEX)
Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4% – Time to Sell?